# Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON)

> **NCT04569461** · PHASE2 · WITHDRAWN · sponsor: **Duke University**

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** pembrolizumab
- **RADIATION:** Low dose prostate radiation
- **PROCEDURE:** Radical Prostatectomy

## Key facts

- **NCT ID:** NCT04569461
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-06
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Discontinuation of funding
- **Last updated:** 2025-07-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04569461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04569461, "Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04569461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*